Discovery of Clinical Candidate NT-0796, a Brain-Penetrant and Highly Potent NLRP3 Inflammasome Inhibitor for Neuroinflammatory DisordersDavid Harrison, Alan P. Watt, Andy Billinton et al.|Journal of Medicinal Chemistry|2023Cited by 62
Reversal of High Fat Diet-Induced Obesity, Systemic Inflammation, and Astrogliosis by the NLRP3 Inflammasome Inhibitors NT-0249 and NT-0796Peter Thornton, Alan P. Watt, Valérie Reader et al.|Journal of Pharmacology and Experimental Therapeutics|2024Cited by 51
Discovery of a series of ester-substituted NLRP3 inflammasome inhibitorsDavid Harrison, Alan P. Watt, Nicolas Boutard et al.|Bioorganic & Medicinal Chemistry Letters|2020Cited by 30
Discovery and Optimization of Triazolopyrimidinone Derivatives as Selective NLRP3 Inflammasome InhibitorsDavid Harrison, Alan P. Watt, Mark G. Bock et al.|ACS Medicinal Chemistry Letters|2022Cited by 23
Target Cell Activation of a Structurally Novel NOD-Like Receptor Pyrin Domain-Containing Protein 3 Inhibitor NT-0796 Enhances PotencyPamela J. Smolak, Christopher A. Gabel, MyTrang Nguyen et al.|Journal of Pharmacology and Experimental Therapeutics|2024Cited by 13